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(n=l,607) and 146 pS/mL for P (n=l,629). For each subgroup, the effect of V on change 
from baseline in aldosterone was analyzed by ANCOVA. Results: P-subtracted least 
squares mean changes from baseline are presented (‘pcO.05 V vs. P). Significant reduc- 
tions in aldosterone from baseline were observed with V at 4, 12, 24 months and at end- 
point in males and females, elderly and non-elderly, and non-black pts. In the small and 
heterogeneous black subgroup, significant reductions in aldosterone were obsewed at 4 
and 12 months with beneficial trend at endpoint (p=O.O67). 
Conclusion: Val produced a sustained reduction in aldosterone in HF patients regard- 
less of age or gender or race. 
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1106-125 Inhibition of Both Neutral Endopeptidase and 
Endothelin Converting Enzyme Lowers Pulmonary 
Pressures in Congestive Heart Failure 
Kenneth Dickstein. Hanka de Vow4 Milutin Miric, Roland Willenbrock, Veselin Mitrovic, 
Richard Pacher, Gabriele Bambasek, Paul Koopman, University of Bergen, Central 
Hospital Ftogaland. Stavanger. Norway, Solvay Pharmaceuticals, Weesp, The 
Netherlands 
Background: SLV306 is an inhibitor of both’neutral endopeptidase and endothelin con- 
verting enzyme. In plasma it increases atrial natriurstic peptide levels and lowers endot- 
helin-1 levels. 
Methods: We studied 75 CHF patients (mean age 60.3 yrs. 91% male, 96% NYHA 
Class 11-111, ejection fraction 24 f 7%) in a double blind, placebo controlled, single oral 
dose hemodynamic study. The dose groups were: SLV306 200mg (n=l6), 400mg 
(n=20), 6OOmg (n=19), and placebo (n=l6). Hemodynamics were measured with a 
Swan-Ganz and anerial catheter for 12 hrs: other medication was withheld. 
Baseline mean hemodynamic values (n=75) were: systolic pulmonary artery pressure 
(SPAP) 44.7 * 16.9 mmf-lg, diastolic pulmonary arlely pressure (DPAP) 21.6 * 6.6 
mmHg, pulmonary capillaty wedge pressure (PCWP) 19.9 * 6.2 mmHg, mean arterial 
pressure (MAP) 93 * 15 mmHg. systemic vascular resistance (SVR) 1,610 + 476 
dynes&n?, and cardiac output (CO) 4.3 + 0.9 I/min. 
Results: Compared to placebo, pulmonary pressures significantly decreased in all 
SLV306 dose groups, with a maximum decrease 6 hrs post dose. No significant effects 
were found for MAP and CO. SVR decreased in the 200 and 6Mlmg_group, but did not 
separate from placebo. Hean rate did not change. 
Change from baseline 6 hrs posi 
dose 
200mg 400mg 600mg place 
bo 
SPAP mmHg -9.9. -11.7 -6.2 + -1.3 
DPAP mmHg -3.6’ -5.7’ -4.7’ -0.1 
PCWP mmHg -5.5’ -6.8’ -4.6+ -1.9 
MAP mmHg -4.4 -5.3 -6.4 -4.5 
SVFtdynessl -166 9 -244 -72 
crri) 
CO Ilmin 0.4 -0.2 0.1 0.1 
* p <0.05,+ p ~0.1 ANCOVA versus placebo 
Baseline adjusted AUC over 12 hrs 
200 400mg 800mg placebo 
mg 
-95’ -112 -72* -10 
-39’ -59’ -41* 4 
-51’ -69’ -&$+ -19 
-65 -68 -68 -47 
- -960 -2,472 -1,350 
2.61 
7 
4.7 -0.1 2.3 2.7 
Conclusion: SLV306 in doses of 200, 400, and BOOmg reduced pulmonary pressures. 
but without a clear dose response. Systemic pressures were maintained. Combined inhi- 
bibon of neutral endopeptidase and endothelin convening enzyme may be useful in CHF 
by lowering LV filling pressures. 
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1107-137 Cholesteryl Ester Transfer Protein Variants Are 
Associated With Plasma Levels of High-Density 
Lipoprotein Cholesterol but Not the Severity or 
Progression of Coronary Atherosclerosis or Response 
to Therapy 
Mehmet Cilineiroalu, Christie M. Ballantyne, Antonio M. Gotto, Jr., Ali J. Marian, Baylor 
College of Medicine, Houston, TX, Weil Medical College of Cornell University, New York, 
NY 
High-density lipoprotein cholesterol is inversely related to coronary atherosclerosis. 
Mutations in cholestelyl ester transfer protein (CEJP) lead to high levels of HDL-C but 
have been implicated in susceptibility to coronary atherosclerosis. We analyzed associa- 
tion of the two most common single nucleotide polymorphisms (SNP) in CETP, namely; 
279G/A and l405V (1394A/G) with plasma levels of HDL-C and other lipoproteins, sever- 
ity and progression of coronary atherosclerosis, response of lipids and atherosclerosis to 
treatment with fluvastatin and clinical outcome in a prospective 2.5 year follow-up study 
of 372 participants of Lipoprotein Coronary Atherosclerosis Study (LCAS). The 279G/A 
and l405V SNPs reoresent two separate common haolotvoes of the CETP rime. Geno- 
typing was performed by polymeiase chain reaction a& restriction map&g. CETP 
SNPs were stronalv associated with olasma levels of HDL-C 1279GIA: GG (n=lll~43.1. 
GA (11x176) 42.8and AA (n=65) 4i.6 mg/dl, p=O.O02) and i405V: II (n=150) 43.4, IV’ 
(n=160) 43.4 and VV (r&2) 46.6. p=O.O21) and similarly with apoA1 (p= 0.006 and 
0.016. respectively). Plasma levels of lowdensity lipoprotein cholesterol and apolipopro- 
teins were not significantly different among the genotypes. There were no association 
between baseline or final quantitative indices of severity of coronary atherosclerosis, 
minimum lumen diameter and the number of coronary lesions were not significantly dif- 
ferent among the genotypes. There were no significant treatment-by-genotype interac- 
tions between the genotypes of two SNPs and response of plasma lipids or coronary 
atherosclerosis to fluvastatin therapy. We conclude CETP SNPs, representing the two 
most common haplotypes. are associated with plasma levels of HDL-C but do not affect 
baseline severity, progression or regression of coronary atherosclerosis 01 response to 
therapy with fluvastatin. 
1107-138 Endothelial and Hepatic Lipase Gene Polymorphisms 
Are Associated With Plasma Levels of High-Density 
Lipoprotein Cholesterol in Lipoprotein Coronary 
Atherosclerosis Study 
Mehmet Cilinairoalu, Silvia Lutucuta, Suet Nee Chen, Antonio M. Gotto. Christie M. 
Ballantyne, Ali J. Marian, Baylor College of Medicine, Houston, TX, Weil Medical College 
of Cornell University, New York, NY 
Plasma level of high-density lipoprotein cholesterol (HDL-C), inversely associated with 
risk of coronary atherosclerosis, is under tight genetic control. It is estimated that at least 
50% of variance of HDL-C levels are genetically determined. However, genetic factors 
that determine plasma levels of HDL-C and thus, the risk of coronary atherosclerosis are 
largely unknown. Recently, a new member of lipase family, namely endothelial lipase 
(L/PC& has been cloned, which has a high homology to hepatic lipase (L/PO and regu- 
lates plasma levels of HDL-C. We analyzed association of two common single nucleotide 
polymorphisms (SNP) in LlPG and L/PC genes, namely; 564CTT SNP in LlPG and - 
514Cil in L/PC with plasma levels of HDL-C and other lipoproteins, severity and pro- 
gression of coronary atherosclerosis, response of lipids and atherosclerosis to treatment 
with fluvastatin and clinical outcome in a prospective 2.5 year follow-up study of 372 par- 
ticipants of LCAS. Genotyping was performed by polymerase chain reaction and restric- 
tion mapping and confirmed by sequencing. L/PC -514C/T SNP was associated with 
plasma levels of HDL-C (CC: 42.5 t 10.7 (n=222), CT: 46.3 + 12.5 (n=l26) and TT: 45.4 
+ 9.2 mg/dl (n=24), p=O.O12) and apolipoprotein (apo) Al (129.7 * 25.4 vs. 137.3 f 30.6 
vs. 140.0 f 20.0, respectively p=O.Ol) and showed a trend toward less severe coronary 
atherosclerosis. There was a modest genotype-by-treatment interaction for changes in 
plasma levels of HDL-C in response to fluvastatin. Baseline severity, progression or 
regression of coronary atherosclerosis were not significant different among the L/PC 
genotypes. Similarly, MPG 564Cfl SNP was associated with plasma levels of HDL-C 
(CC: 42.6 * 10.2 (,x165), CT: 44.7 * 12.2, TT: 49.6 + 13.5, p=O.O26) and modestly with 
apoA1 levels (p=O.O9). There were no significant genotype-by-treatment interactions 
between LIPG genotypes and response of plasma HDL-C to treatment or with baseline 
severity, progression or regression of coronary atherosclerosis. We conclude common 
L/PC and LlPG SNPs are associated with plasma levels of HDL-C. The L/PC SNP also 
showed a modest association with baseline severity of coronary atherosclerosis and 
response to therapy. 
